Gilead Sciences (GILD) Exchange Rate Effect (2009 - 2026)
Gilead Sciences' (GILD) quarterly Exchange Rate Effect came in at -$19.0 million in Q2 2026, down 126.03% on a YoY basis from $73.0 million in Q2 2025, and down 72.73% quarter-over-quarter from -$11.0 million in Q1 2026.
Analysis
Gilead Sciences (GILD) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Exchange Rate Effect for 18 consecutive years, with -$19.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Exchange Rate Effect fell 126.03% year-over-year to -$19.0 million; the trailing twelve-month figure through Jun 2026 stood at -$30.0 million (down 137.04% YoY), and the FY2025 full-year result was $92.0 million, up 330.0% from the prior year.
- Exchange Rate Effect declined to -$19.0 million in Q2 2026 per GILD's latest filing, from -$11.0 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $75.0 million in Q4 2022 and bottomed at -$72.0 million in Q3 2022.
- Historically, Exchange Rate Effect has averaged $888888.9 across 5 years, with a median of -$5.5 million in 2023.
- The widest YoY moves for Exchange Rate Effect: up 933.33% in 2022, down 340.0% in 2022.
- Over 5 years, Exchange Rate Effect stood at $75.0 million in 2022, then tumbled by 50.67% to $37.0 million in 2023, then sank by 248.65% to -$55.0 million in 2024, then soared by 109.09% to $5.0 million in 2025, then tumbled by 480.0% to -$19.0 million in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$19.0 million, -$11.0 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | -287,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.00 Mn |
| Mar 31, 2026 | -11.00 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | -5.00 Mn |
| Jun 30, 2025 | 73.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | -55.00 Mn |
| Sep 30, 2024 | 44.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -18.00 Mn |
| Dec 31, 2023 | 37.00 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | 13.00 Mn |
| Mar 31, 2023 | 13.00 Mn |
| Dec 31, 2022 | 75.00 Mn |
| Sep 30, 2022 | -72.00 Mn |
| Jun 30, 2022 | -48.00 Mn |
| Mar 31, 2022 | -18.00 Mn |
| Dec 31, 2021 | -9.00 Mn |
| Sep 30, 2021 | -23.00 Mn |